BACKGROUND: Transformation of @entity706 ( @entity706 ) @entity146 ( @entity146 ) often results in a rapid clinical course, treatment refractoriness and shortened survival. Although rituximab-containing regimens (R-chemo) have become standard of care in @entity2225 -positive @entity146 , the role of autologous stem-cell transplantation (ASCT) is still debated. The purpose of this study was to determine whether the outcome of @entity146 @entity1 improved if they, at transformation, also received ASCT. Furthermore, we investigated the outcome of cases with histologically low- and high-grade components diagnosed either simultaneously or after a period of overt indolent disease. We also analyzed, whether prior rituximab treatment during the indolent course of the disease affected outcome after transformation. @entity1 AND METHODS: Eighty-five @entity1 ( <=68 years) with histologically confirmed @entity146 were included. Five-year overall ( @entity3012 ) and progression-free survival (PFS) were calculated. Selected parameters were tested in a multivariate analysis. All analyses were conducted on three cohorts: (i) whole cohort (all @entity146 ), (ii) @entity1 with co-existing evidence of both indolent and aggressive histology at diagnosis (Composite/discordant @entity146 ) and (iii) @entity1 transformed after prolonged prior indolent disease (sequential @entity146 ). RESULTS: Fifty-four @entity1 (64%) received ASCT consolidation and 31 (36%) did not. Within the 'all @entity146 ' cohort, the 5-year @entity3012 and PFS for R-chemo + ASCT versus R-chemo alone, were 67% versus 48% (P = 0.11) and 60% versus 30% (P = 0.02), respectively. Furthermore, in 'Composite/discordant @entity146 ' R-chemo + ASCT showed no impact on @entity3012 (76% versus 67%; P = 0.66) or PFS (71% versus 62%; P = 0.54). Conversely, R-chemo + ASCT improved the outcome of 'sequential @entity146 ' ( @entity3012 62% versus 36%; P = 0.07; PFS 53% versus 6%; P = 0.002), regardless of prior rituximab therapy. The beneficial effect of ASCT was significantly higher in @entity1 who had not received rituximab at @entity706 stage. CONCLUSIONS: ASCT improved the outcome in sequential, but not composite/discordant @entity146 . The beneficial impact of ASCT was greater in @entity1 , who were rituximab-na  ve at transformation.

Outcome determinants for transformed XXXX treated with or without autologous stem-cell transplantation.

@entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS'] @entity706 :: ('MESH:D008223', 'Disease') :: ['indolent lymphomas', 'IL'] @entity3012 :: ('MESH:C567932', 'Disease') :: ['OS'] @entity146 :: ('MESH:D001523', 'Disease') :: ['TIL', 'to an aggressive histology'] @entity2225 :: ('54474', 'Gene') :: ['CD20']
@entity706 :: (MESH:D008223,Disease) :: ['indolent lymphomas']
